How to appeal a Horizon Blue Cross Blue Shield of New Jersey plaque psoriasis + psoriatic arthritis denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Horizon Blue Cross Blue Shield of New Jersey-specific note: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).

What Horizon Blue Cross Blue Shield of New Jersey's policy requires for plaque psoriasis + psoriatic arthritis

Cited policy: BCBS Humira / Adalimumab Biosimilar PsA + Plaque PA

Plaque: BSA >=3% with special-site or BSA >=10% / PASI >=12 / DLQI >=10. PsA: ACR criteria + active disease (TJC/SJC >=3 or axial/enthesitis/dactylitis) + MTX failure or contraindication. Mandatory adalimumab biosimilar substitution (Cyltezo interchangeable preferred) unless dispense-as-written justification.

How Horizon Blue Cross Blue Shield of New Jersey denies plaque psoriasis + psoriatic arthritis — and how to counter it

Where Horizon Blue Cross Blue Shield of New Jersey pushes back: 1) MTX trial inadequate for PsA; 2) Must use Cyltezo/biosimilar instead of branded Humira; 3) BSA <3%; 4) Latent TB / HBV not screened.

Counter-arguments that hold up: ACR/NPF 2018 PsA (Singh) + GRAPPA 2021 + EULAR 2023 PsA — severe peripheral arthritis / axial / enthesitis / dactylitis / erosive disease can go directly to TNFi without MTX trial. SEAM-PsA: MTX inferior to etanercept wk 24. REVEAL (Menter JAAD 2008) PASI 75 71% wk 16. CHAMPION — Humira > MTX. For Cimzia: pregnancy-friendly (no Fc receptor → no transplacental transfer; Mariette ARD 2018). Biosimilar substitution acceptable but does NOT bypass primary-failure class-switch — failing branded Humira predicts failing biosimilar (same molecule).

What Horizon Blue Cross Blue Shield of New Jersey typically denies for plaque psoriasis + psoriatic arthritis

Across Horizon Blue Cross Blue Shield of New Jersey's commercial and Medicare books, denials cluster around a small number of patterns. For plaque psoriasis + psoriatic arthritis, expect:

• OMNIA tier-1 vs tier-2 provider disputes
• Step therapy on biologics
• Behavioral health prior auth
• Out-of-state emergency reductions

Treatments most often denied in this category

These are the plaque psoriasis + psoriatic arthritis treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira
• Enbrel
• Remicade
• Cimzia
• Simponi
• Cosentyx

How to submit the appeal to Horizon Blue Cross Blue Shield of New Jersey

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Horizon Blue Cross Blue Shield of New Jersey cited in the denial.
3. File the appeal through Horizon Blue Cross Blue Shield of New Jersey's portal (members: https://www.horizonblue.com ; providers: https://www.horizonblue.com/providers). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In NJ, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Horizon Blue Cross Blue Shield of New Jersey's prior-authorization criteria by drug: Horizon Blue Cross Blue Shield of New Jersey PA criteria on ApprovalHelp.